Delivery Order SPE2DB22D3501-SPE2DB25FWV05
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on August 4, 2025, by the Defense Logistics Agency (DLA) for Dupixent 200 mg/1.14 ml pen auto-injectors. The contract is valued at $1,935.84 with a firm fixed price structure and an ultimate completion date of August 5, 2025. This non-competitive delivery order was issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $25,796.42 on August 21, 2025, by the Defense Logistics Agency's Medical Supply Chain to supply DUPIXENT 300 mg/2 mL pens. The contract is a firm fixed-price delivery order with an ultimate completion date of August 22, 2025, and was competitively awarded without a set-aside designation. This award represents a child order under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $8,931.71 to AmerisourceBergen Drug Corp for DUPIXENT 300 mg/2 mL pen auto-injectors (2 mL) on September 2, 2025, with completion targeted for September 3, 2025. This non-competitive, firm fixed-price delivery order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a $22,738.07 firm fixed price delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 MG/2 ML pen injectors (2 ML). The contract was executed on July 29, 2025, with an ultimate completion date of July 30, 2025, and is being fulfilled at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a non-set-aside, competitively awarded contract issued under the company's existing Indefinite Delivery Contract...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 mg/2 ml pen injections with a ceiling value of $14,224.59 under a firm fixed-price contract type. The award was made on September 23, 2025, with an ultimate completion date of September 24, 2025, and does not utilize a set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical...
- The Defense Logistics Agency awarded a $26,840.77 delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 MG/2 ML pen injectors on September 24, 2025, with completion scheduled for September 25, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical products will be performed at the company's corporate...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $20,072.57 on August 7, 2025, for the supply of DUPIXENT 300 mg/2 ml pen injectors (2 ml units). The contract employs firm fixed pricing with no set-aside designation, indicating competitive award. Performance will be executed at AmerisourceBergen's corporate facility in Conshohocken, Pennsylvania, with an ultimate completion date of August 8, 2025. This delivery order is a child contract under...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at approximately $24,000 on August 25, 2025, by the Department of Defense Medical Supply Chain to supply Dupixent 300 mg/2 mL pen injectors. The contract is non-competitive, firm fixed-price, and carries an ultimate completion date of August 26, 2025, with performance occurring at the vendor's Conshohocken facility. This delivery order is executed under...
- AmerisourceBergen Drug Corp was awarded a delivery order on September 3, 2025, by the Defense Logistics Agency (DLA) for DUPIXENT 300 mg/2 ml pen injectors valued at $10,570.09 under a firm fixed-price contract. The order is set to be completed by September 4, 2025, with performance conducted at the company's corporate office location in Conshohocken, Pennsylvania. This competitively awarded delivery order represents a single pharmaceutical supply transaction within DLA's medical procurement...
- The Defense Logistics Agency awarded a $16,294.08 firm fixed-price delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 mg/2 ml pen injections (2 ml units) on September 9, 2025, with an ultimate completion date of September 10, 2025. This non-competitive, competitively-awarded contract is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB25FWV05Delivery Order
AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency (DLA) on August 11, 2025, with an ultimate completion date of August 12, 2025. The contract, valued at $17,950.70 under firm fixed pricing, covers the supply of DUPIXENT 200 MG/1.14 ML pen injectors. This award represents a competitive, non-set-aside delivery order executed under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), an approximately $1 billion global pharmaceutical support vehicle running through December 2026. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order supports the Defense Health Agency's pharmaceutical supply requirements through AmerisourceBergen's established role as a prime pharmaceutical vendor for the Department of Defense. DUPIXENT is a biologic medication used to treat conditions such as eczema, asthma, and chronic rhinosinusitis, making this procurement part of the DLA's broader medical supply chain supporting military healthcare systems. The firm fixed price and rapid completion timeline reflect the expedited nature of this specific pharmaceutical delivery within the comprehensive IDC framework that enables AmerisourceBergen to fulfill diverse federal medical commodity needs across therapeutic domains worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $18.0k | 8/11/25 |